IGM Biosciences is pioneering a new class of antibody medicines for the treatment of cancer, infectious diseases and autoimmune and inflammatory diseases. Building upon the greater binding power provided by the naturally occurring IgM antibody structure, as compared with the commonly-used IgG antibody structure, IGM has been able to create “super antibodies” with the potential to generate novel therapeutic options and hope for patients.
» LEARN MORE ABOUT WHAT SETS US APART
REIMAGINING
antibody medicines
Reimagining antibody medicines
We believe we have the world’s most advanced research and development program focused on engineered therapeutic IgM antibodies.
Using our expertise to expand upon and improve the inherent qualities of IgM antibodies and produce them at scale, we aim to develop a range of therapeutic antibodies for the treatment of cancer, infectious diseases and autoimmune and inflammatory diseases.
Exploring scientific boundaries
By developing this new class of antibodies,
we have opened up new approaches to treating disease.
» Learn more about our lead programs in cancer and infectious disease
Make an impact at IGM
Help us to bring a new class of antibody medicines to patients.
Recent News
May 10, 2022
May 9, 2022
April 6, 2022
Featured
A Phase 1 Dose Escalation Study of IGM-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies
63rd American Society of Hematology (ASH) Annual Meeting and Exposition, December 11-14, 2021
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
Published in Molecular Cancer Therapeutics, October 28, 2021
Authors: Wang, B.T. et al
